基蛋生物科技股份有限公司 基蛋生物科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 展规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司董事会提议拟以实施权益分派股权登记日总股本数为基数（具体日期将在权益分派实施公告 中明确，在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额不变，相应调整每 股分配比例） 基蛋生物科技股份有限公司2025 年半年度报告摘要 公司代码：603387 公司简称：基蛋生物 ，向全体股东每 10 股派发人民币 0.9 元（含税），以第四届董事会第七次会议召开日的前 一个 交易日 （即 2025 年 8 月 28 日） 总股本 507,153,517 股进 行计算 ，本次 共计派发 现金股 利 此次现金分红占 2025 年半年度合并报表归属于上市公司股东的净利润比例为 41.95%。 根据公司 2024 年年度股东大会对 2025 年度中期分红事宜的相关授权，本次利润分配方案无需 提 交股东大会审议。 | | 第二节 | 公司基本情况 | | | | ...

Core Viewpoint - The company held an online performance briefing on May 27, 2025, to discuss its 2024 annual and 2025 Q1 performance, addressing investor concerns and highlighting operational and financial conditions [1]. Group 1: Financial Performance - The company's gross margin for 2024 increased by 2.86 percentage points to 69.23%, attributed to supply chain management optimization and product structure adjustments, despite a decline in operating revenue [2]. - In Q1 2025, the company achieved operating revenue of 244 million yuan, with overseas conventional product revenue reaching 47 million yuan, a year-on-year increase of 66.51% [2]. Group 2: Business Strategy and Market Position - The company is responding to industry challenges such as centralized procurement and DRG policies by optimizing sales strategies and enhancing service systems to maintain stable business development [4]. - The Metis6000 fully automated biochemical immunoassay line targets secondary and lower-tier hospitals, with over 70% of installations in these facilities, indicating a clear market positioning strategy [4][5]. Group 3: Product Development and Innovation - The Metis7000 fully automated biochemical immunoassay line is in the trial production phase, aiming to enhance performance and cost-effectiveness, with a broad testing menu covering nearly 400 items [5]. - The company plans to further increase the proportion of its chemiluminescence business, which accounted for 26.72% of self-produced product revenue in 2024, growing by 31.14% year-on-year [4]. Group 4: International Expansion - The company has established a presence in 66 countries and regions, holding over 2,500 overseas registration certificates and product import permits, with a focus on expanding its market share in Europe, Asia, and Latin America [5].